Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05487599
Other study ID # J3Z-MC-OJAE
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 20, 2022
Est. completion date October 2, 2030

Study information

Verified date May 2024
Source Prevail Therapeutics
Contact Prevail Therapeutics
Phone (917) 336-9310
Email Prevail.Patients@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients. Following this, up to 6 patients may be enrolled into an expansion cohort. For each enrolled patient, the study will be approximately 5 years in duration, including up to a 45-day screening period. During the first 18 months after dosing, subjects will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 42 months to monitor safety, immunogenicity, and selected biomarker and efficacy parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date October 2, 2030
Est. primary completion date October 2, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age 18-65 years inclusive at the time of informed consent. 2. Bi-allelic GBA1 mutations must be centrally confirmed. 3. On ERT or SRT for at least 2 years and on a stable, maximum tolerated dose, for at least 3 months prior to screening. 4. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 5. Females and males will be eligible for this study. Men and women of childbearing potential must use a highly effective method of contraception consistently and correctly for the duration of the study, including the long-term follow-up. 6. Patients must agree to abstain from blood donations for at least the first year of the study. Exclusion Criteria: 1. Clinically significant neurological signs and symptoms and/or behavioral disturbances. 2. Active and progressive bone disease expected to require surgical treatment in the next 6 months. 3. History of total splenectomy or planned total splenectomy during the first 18 months of the study. (Partial splenectomy not exclusionary). 4. Splenomegaly > 10 MN as evaluated by centrally read abdominal MRI 5. Evidence of clinically significant liver disease, fragile liver, or history of exposure to hepatotoxins. 6. Thrombocytopenia with platelet count < 40 × 103 per µL. 7. Severe hyperlipidemia (triglycerides > 1,000 mg/dL). 8. Current diagnosis of unstable or clinically significant cardiovascular conditions based on Investigator assessment. 9. History of certain cancers within 5 years of Screening. 10. Concomitant disease, condition or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. 11. Women of childbearing potential, pregnant (i.e., positive serum pregnancy result at Screening and Day 1) or breastfeeding or intending to become pregnant during the course of the trial. 12. Use of any GD-related chaperone therapy within 4 weeks prior to Screening or expected need to initiate chaperone therapy during at least the first 18 months of the study. 13. Any type of prior gene or cell therapy. 14. Use of systemic immunosuppressant or steroid therapy other than protocol-specified immunosuppression. 15. Participation in another therapeutic investigational drug or device study within 3 months or 5 half-lives of the study agent, whichever is longer. 16. Have an anti-AAV9 antibody titer of >1:40 as determined by central laboratory. 17. Clinically significant abnormalities in laboratory test results at Screening. 18. Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic)implants/cardiac pacemaker.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
LY3884961
• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.

Locations

Country Name City State
Germany SphinCS Clinical Science for LSD Hochheim
Spain Hospital Universitario Ramon y Cajal, Calle Colmenar Viejo Km 9100 Madrid
Spain Hospital Quironsalud Zaragoza, Paseo Mariano Renovales Sn Zaragoza
United States Duke University Health System Durham North Carolina
United States Lysosomal Rare Disorders Research and Treatment Center Fairfax Virginia

Sponsors (2)

Lead Sponsor Collaborator
Prevail Therapeutics Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) with AE's graded as mild, moderate, or severe. 5 years
Secondary Spleen volume Change and percent change from baseline 5 years
Secondary Platelet count Change from baseline 5 years
Secondary GCase levels Change from baseline 5 years
Secondary GluSph levels Change from baseline 5 years
Secondary Discontinuation of enzyme replacement therapy (ERT)/substrate reduction therapy (SRT) Time from dosing to discontinuation of ERT/SRT 5 years
Secondary Re-initiation of ERT/SRT (if necessary) Time to re-initiation of ERT/SRT (if necessary) Time to re-initiation of ERT/SRT (if necessary) 5 years
See also
  Status Clinical Trial Phase
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT02536911 - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate Phase 1
Completed NCT04430881 - A National Study in Patients With Unexplained Splenomegaly
Completed NCT02536937 - A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate Phase 1
Completed NCT01411228 - A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease Phase 3
Terminated NCT04094181 - A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Completed NCT00391625 - Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT) Phase 1/Phase 2
Completed NCT03625882 - Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Active, not recruiting NCT05526664 - Omics Gaucher Study: Multiomic Approach
Completed NCT02536755 - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies Phase 3
Recruiting NCT01344096 - Thrombocytopathy in Gaucher Disease Patients N/A
Completed NCT01881633 - A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers Phase 1
Recruiting NCT06116071 - Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting NCT01951989 - Intra-monocyte Imiglucerase Kinetics in Gaucher Disease Phase 2
Completed NCT00258778 - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) Phase 1
Recruiting NCT04388969 - World Data on Ambroxol for Patients With GD and GBA Related PD
Recruiting NCT05992532 - GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Terminated NCT04145037 - Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease Phase 1/Phase 2
Completed NCT00302146 - Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Active, not recruiting NCT02605603 - SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease